首页> 美国卫生研究院文献>RMD Open >Original research: Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3 randomised controlled trials

【2h】

Original research: Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3 randomised controlled trials

机译：原始研究：ustekinumab对没有TNFi的活动性银屑病关节炎合并医师报告的脊柱炎患者的脊柱炎相关终点的影响：来自两项3期随机对照试验的合并结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The interleukin-12/23p40-subunit-inhibitor ustekinumab significantly improved spondylitis-related symptoms through Week 24 in psoriatic arthritis (PsA) patients with peripheral arthritis and physician-reported spondylitis (PA-PRS) in PSUMMIT-1&2. We further evaluated ustekinumab’s effect on spondylitis-related endpoints in PSUMMIT-1&2 tumour necrosis factor-inhibitor (TNFi)-naïve patients with PA-PRS.

机译：白细胞介素12 / 23p40亚基抑制剂ustekinumab通过银屑病关节炎（PsA）伴有外周关节炎和医师报告的脊柱炎（PA-PRS）患者的PSUMMIT-1＆2可以显着改善与脊柱炎相关的症状。我们进一步评估了乌斯他单抗对PSUMMIT-1＆2单纯性肿瘤坏死因子抑制剂（TNFi）的PA-PRS患者的脊柱炎相关终点的影响。

著录项

期刊名称 RMD Open
作者
Philip S Helliwell; Dafna D Gladman; Soumya D Chakravarty; Shelly Kafka; Chetan S Karyekar; Yin You; Kim Campbell; Kristen Sweet; Arthur Kavanaugh; Lianne S Gensler;
展开▼
作者单位

展开▼
年(卷),期 2020(6),1
年度 2020
页码 -1
总页数 8
原文格式 PDF
正文语种
中图分类
关键词
psoriatic arthritis; axial disease; interleukin-12/23; ustekinumab;

机译：银屑病关节炎;轴性疾病;白介素-12/23;ustekinumab;
入库时间 2022-08-21 11:45:07

相似文献

外文文献
中文文献
专利

1. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials [J] . KavanaughA., RitchlinC., RahmanP., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第6期

机译：Ustekinumab，一种抗IL-12 / 23 p40单克隆抗体，抑制活动性银屑病关节炎患者的放射学进展：来自3期，多中心，随机，双盲，安慰剂对照的PSUMMIT-的放射学数据的综合分析结果1和PSUMMIT-2试用
2. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial [J] . RitchlinC., RahmanP., KavanaughA., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第6期

机译：抗IL-12/23 p40单克隆抗体，Ustekinumab，在患有常规非生物和生物抗肿瘤坏死因子治疗的患者中，抗IL-12/23 p40单克隆抗体，Ustekinumab的功效和安全性：6个月和1年的第3阶段结果，多中心，双盲，安放的，随机的psummit 2试验
3. Original article: Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond [J] . Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, RMD Open . 2019,第1期

机译：原始文章：托法替尼对活动性银屑病关节炎患者报告的结局的影响，并且在III期随机对照试验中对肿瘤坏死因子抑制剂的反应不足：OPAL Beyond
4. Synbiotic Therapy Significantly Reduces Molecular Markers of Inflammation and Clinical Scores in Patients with Active Ulcerative Colitis; A Randomised Controlled Trial [C] . Controlled Release Society annual meeting . 2004

机译：同步治疗显着减少了活性溃疡性结肠炎患者的炎症和临床评分的分子标记;随机对照试验
5. Hypotensive resuscitation versus standard fluid resuscitation for the management of trauma patients in hemorrhagic shock: The safety phase of a randomized controlled trial. [D] . Morrison, C. Anne. 2009

机译：低血压复苏与标准液体复苏在失血性休克中对创伤患者的处理：一项随机对照试验的安全性阶段。
6. Extended report: Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody ustekinumab in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3 multicentre double-blind placebo-controlled randomised PSUMMIT 2 trial [O] . Christopher Ritchlin, Proton Rahman, Arthur Kavanaugh, -1

机译：扩展报告：抗IL-12 / 23 p40单克隆抗体ustekinumab在活动性银屑病关节炎患者中的疗效和安全性尽管采用传统的非生物和生物抗肿瘤坏死因子疗法：6个月和1年的结果3期多中心双盲安慰剂对照随机PSUMMIT 2试验
7. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial [O] . Ritchlin, C., Rahman, P., Kavanaugh, A., 2014

机译：尽管常规的非生物和生物抗肿瘤坏死因子治疗，抗IL-12/23 p40单克隆抗体ustekinumab在活动性银屑病关节炎患者中的疗效和安全性：第3阶段的6个月和1年结果，多中心，双盲，安慰剂对照，随机psUmmIT 2试验

Original research: Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3 randomised controlled trials

摘要

著录项

相似文献

相关主题

期刊订阅